Loyal is pioneering the field of canine longevity by developing the first FDA-approved drugs aimed at extending healthy lifespan in dogs. Loyal’s innovative approach targets the underlying mechanisms of aging, with three drugs in development—LOY-001, LOY-002, and LOY-003—designed to extend the healthy lifespan of large-breed and senior dogs. Pending FDA approval, the company anticipates launching its first product in early 2025, offering pet owners more precious years with their beloved companions.
Sector: Pet Biotechnology
Co-investors: Bain Capital Ventures, Koshla Ventures, First Round Capital, Box Group, Collaborative Fund, Quiet Capital, and Valor Equity Partners